High genetic diversity of Staphylococcus aureus strains colonising the nasopharynx of Gambian villagers before widespread use of pneumococcal conjugate vaccines. by Ebruke, Chinelo et al.
Ebruke, Chinelo; Dione, Michel M;Walter, Brigitte; Worwui, Archibald;
Adegbola, Richard A; Roca, Anna; Antonio, Martin (2016) High ge-
netic diversity of Staphylococcus aureus strains colonising the na-
sopharynx of Gambian villagers before widespread use of pneumococ-
cal conjugate vaccines. BMCMicrobiology, 16 (1). DOI: https://doi.org/10.1186/s12866-
016-0661-3
Downloaded from: http://researchonline.lshtm.ac.uk/4650290/
DOI: 10.1186/s12866-016-0661-3
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
High genetic diversity of Staphylococcus
aureus strains colonising the nasopharynx
of Gambian villagers before widespread
use of pneumococcal conjugate vaccines
Chinelo Ebruke1,3, Michel M. Dione1, Brigitte Walter1, Archibald Worwui1, Richard A. Adegbola4, Anna Roca2
and Martin Antonio1,3,5*
Abstract
Background: With the global efforts of reducing pneumococcal disease through widespread introduction of
pneumococcal vaccines, concerns have emerged on the potential increase of morbidity and mortality from S.
aureus disease. Little is known however, of the carriage rates of S. aureus or of its’ relationship with carriage of S.
pneumoniae in rural Africa, and West Africa in particular where very high rates of carriage of S. pneumoniae have
been reported. This study aims to evaluate the prevalence, antibiotic susceptibility patterns and genotypes of S.
aureus isolated from the nasopharynx of healthy individuals in rural Gambia before the introduction of routine use
of pneumococcal conjugate vaccines in the country.
Results: Overall prevalence of S. aureus nasopharyngeal carriage was 25.2 %. All S. aureus isolates tested were
susceptible to methicillin. Resistant was observed for sulphamethoxazole-trimethoprim (15 %) and tetracycline
(34.3 %). We found 59 different sequence types (ST), 35 of which were novel. The most prevalent sequence types
were ST 15 (28 %) and ST 5 (4 %). Eighty two percent (494/600) of study individuals were S. pneumoniae carriers
with S. pneumoniae carriage rates decreasing with increasing age groups. S. aureus carriage among pneumococcal
carriers was slightly lower than among non-pneumococcal carriers (24.3 versus 29.3 %; p = 0.324). There were no
associations of carriage between these two bacteria across the 4 age groups. However, analysis of pooled data
children < 2 years and children 2 to < 5 years of age showed a statistically significant inverse association (24.1 and
50.0 % for S. aureus carriage among S. pneumoniae carriers and non-carriers respectively; p = 0.015).
Conclusions: We report that nasopharyngeal carriage of S. aureus in rural Gambia is high in all age groups, with
approximately 1 out of 4 individuals being carriers in the pre-pneumococcal vaccination era. There are indications
that nasopharyngeal carriage of S.aureus could be inversely related to carriage of S. pneumoniae amongst younger
children in The Gambian and that S. aureus clones in The Gambia show significant genetic diversity suggesting
worldwide dissemination. Findings from this study provide a useful background for impact studies evaluating the
introduction of pneumococcal vaccines or other interventions targeting the control of S. aureus infections and
disease.
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Background
Staphylococcus aureus is a common cause of nosocomial
and community acquired infections worldwide and results
in significant morbidity and mortality in children and
adults [1–3]. Surveillance data from both the developed
and the developing world, including Africa, report S.
aureus as one of the leading causes of invasive bacterial
infections among young children with incidence rates
peaking in newborns [4, 5]. Invasive S. aureus disease is
assuming increasing importance globally with the emer-
gence of drug-resistant and community associated
methicillin resistant strains [6].
The anterior nares and the nasopharynx are recognised
as colonization sites of S. aureus and an important ante-
cedent to subsequent invasive S. aureus disease [7, 8].
Nasopharyngeal carriage studies have been used in screen-
ing programmes for early detection of individuals at high
risk for invasive S. aureus disease [9].
Another leading cause of human infection and death is
Streptococcus pneumoniae, also frequently found in the
nasopharynx of healthy individuals. Some studies have
reported an inverse relationship between carriage of S.
aureus and S. pneumoniae both before [10–12] and after
[13] the use of pneumococcal conjugate vaccines. With
increasing global efforts of reducing pneumococcal disease
through widespread introduction of pneumococcal
vaccines, concerns have emerged on the potential
increase of morbidity and mortality from S. aureus
disease. Little is known however, on carriage rates of
S. aureus and the relationship between carriage of S.
aureus and S. pneumoniae in rural Africa [14]. This
could be particularly important in West Africa where
very high rates of carriage of S. pneumoniae have
been reported [15, 16].
This study aims to evaluate the prevalence, antibiotic
susceptibility patterns and genotypes of S. aureus isolated
from the nasopharynx of healthy individuals resident in
rural Gambia before the introduction of pneumococcal
conjugate vaccines as part of the Expanded Programme of
Immunization in the country. Associations between the
isolation of S. aureus and S. pneumoniae in the nasophar-
ynx were also evaluated.
Methods
Study population
Samples used for this study were obtained from a cross
sectional survey conducted in between 2003 and 2004 as
described elsewhere [15]. Briefly, 21 villages in Western
Division, The Gambia, located outside the region where
a previous pneumococcal vaccine efficacy trial was
undertaken [17], were selected for this survey. The
population comprised predominantly subsistence farmers
and belonged mainly to the Jola and Mandinka ethnic
groups. The prevalence of HIV infection was 2–3 % [18].
The Gambia Government/MRC Joint Ethics Committee
approved the study. Trained field workers/nurses ex-
plained the contents of the study information sheet to
parents/guardians in their own language. Adult partici-
pants gave written informed consent prior to enrolment.
Parents/guardians of all children participants gave written
informed consent prior to enrolment.
Study design
To obtain a balanced sample of subjects from different
age groups, one nasopharyngeal swab (NPS) per child
was collected from all children less than 5 years of age
and adults 50 years and above and from a random 1 in 2
sample of individuals age 5–49 years [15]. A total of
2972 NPS were collected using calcium alginate swabs
(Fisher Brand ®, USA and immediately inoculated into
vials containing skim milk tryptone glucose glycerol
(STGG) transport medium (Oxoid, Basingstoke, UK).
Inoculated swabs were transported to the Medical
Research Council Laboratories, Fajara (a distance of
90 km) in a cold box within 8 h of collection in accord-
ance with the World Health Organization protocol for
evaluation of carriage [19]. Inoculated vials were stored
at −70 °C until ready for testing in batches. S. pneumo-
niae was isolated and antibiotic susceptibility testing and
serotyping were done using standard techniques [15].
For the purpose of the current study, a random selec-
tion of 600 NPS of the 2972 samples collected were in-
cluded for analysis. Randomization was age-adjusted to
obtain 150 samples in each study age category, grouped
as < 2 years, 2 to < 5 years, 5 to < 15 years and ≥ 15 years.
Microbiology laboratory investigations
For isolation of S. aureus, 100 μl of thawed NPS was
plated out on 5 % sheep Blood Agar (BA) and Mannitol
Salt Agar (MSA) plates (Oxoid, Basingstoke, UK) which
were aerobically incubated at 37 °C for 24 and 48 h re-
spectively. BA plates were examined for pale to golden
yellow doomed shaped colonies 4–5 mm in diameter
showing alpha haemolysis while MSA plates were exam-
ined for mannitol fermenting colonies. These were sub-
cultured on 5 % sheep BA plates overnight. Cultures
were tested by Slidex Staph kit (Biomerieux, Basingstoke,
Hampshire, UK), a rapid latex and red blood cell agglu-
tination test for the identification of S. aureus. Positive
cells were tested for antibiotic sensitivity by disk diffu-
sion for a wide range of antibiotics (Oxoid, Basingstoke,
UK) including oxacillin (1 μg), chloramphenicol (30 μg),
trimethoprim-sulphamethazole (1.25/23.75 μg), erythro-
mycin (15 μg), tetracycline (30 μg) and cefotaxime
(30 μg)following CLSI guidelines [20]. Isolates that
showed intermediate resistance to oxacillin were further
screened with cefoxitin disk (30 μg) to rule out methicil-
lin resistance. The MRC Unit The Gambia, molecular
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microbiology laboratory submits to the external quality
assurance programme of the UK National External
Quality Assessment Service [21] and is a World Health
Organization (WHO) Regional Reference Laboratory for
invasive bacterial pathogens.
Multilocus sequencing typing (MLST)
MLST was performed on an age-adjusted random selec-
tion of 100 S. aureus isolates to obtain 25 samples in
each study age category. Isolates were streaked on blood
agar and incubated at 37 °C for 18 h. A single colony
from each isolate was picked, streaked and incubated at
37 °C for 18 h. Genomic DNA were prepared from a
loopful of bacteria as described in the manufacturer's in-
structions (Qiagen Genomic DNA Kit, Manchester, UK).
MLST was performed as described previously [22]. Se-
quences were edited and complementary sense antisense
fragments were aligned using the Laser Gene DNA star
7.1 software. Finally, the sequences were submitted to
the MLST database website (http://saureus.mlst.net) and
assigned to existing or novel allele or sequence type
numbers defined by the database. STs were analysed for
relatedness using the eBURST v3 program (eburst.mlst.-
net). A clonal complex (CC) was defined as a group of
sequence types (STs) sharing 6/7 alleles with at least one
other member of the group; while a singleton was
defined as an ST that cannot be linked to any sample.
Cluster analysis of allelic profiles was performed using a
categorical coefficient and a graphic method called a
minimum spanning tree with Bionumerics software (ver-
sion 6.5; Applied Maths, Sint-Martens-Latem, Belgium).
Data management and statistical analysis
Data were double entered into an ACCESS database and
checked for range and consistency. For each of the four
age groups, univariable analyses were used to assess
whether S. pneumoniae carriage was significantly associ-
ated with S. aureus carriage using Chi squared or Fisher’s
exact test, where appropriate. A logistic regression model
was then fitted including the variables age group, gender
and ethnicity. To test for an interaction between the
variables age group and S. pneumoniae a log likelihood ra-
tio test was performed. STATA (version 11, Stata Corpor-
ation, College Station TX) was used for all analyses.
Results
S. aureus carriage
For analysis of S. aureus carriage, we included NPS sam-
ples collected from 600 individuals with 150 in each of
the four study age groups. The overall prevalence of S.
aureus nasopharyngeal carriage was 25.2 % (n = 151).
Stratifying by age group, S. aureus carriage was 20.0 %
(30/150) for children < 2 years; 31.3 % (47/150) for chil-
dren 2 to < 5 years; 23.3 % (35/150) for ages 5 to < 15 years
and 26.0 % (35/150) for individuals ≥ 15 years (p = 0.140).
There was no significant difference in carriage prevalence
by gender (46 % females versus 54 % for males; p = 0.336).
Antibiotics susceptibility testing of S. aureus isolates
Antibiotic susceptibility was tested on 93 % of S. aureus
isolates (140/151). Overall susceptibility to tested anti-
biotics was high for oxacillin, chloramphenicol and
cefotaxime (100, 93.6, and 93.6 % susceptible isolates,
respectively). Susceptibility was lower for erythromycin,
sulphamethoxazole-trimethoprim and tetracycline (63.6,
77.1 and 62.9 % susceptible isolates, respectively),
although resistant isolates were only found for
sulphamethoxazole-trimethoprim and tetracycline (15 and
34.3 % of overall isolates, respectively). Susceptibility to
erythromycin increased with age groups (p = 0.015,) and
children < 2 years were less susceptible to all antibiotics
than older children and adults (Table 1).
Multilocus sequence typing and population biology of S.
aureus isolates
MLST was performed using 100 study isolates (66 % of
151 S. aureus isolates obtained). With these bacteria we
found 59 different sequence types (ST), 35 of them being
novel. In addition, one new allele pta (220) was discov-
ered. The most prevalent sequence types were ST15
(28 %) and ST5 (4 %) (Table 2). eBURST analysis using
the stringent 6/7 identical loci definition grouped our
Table 1 Antibiotics susceptibility pattern of S. aureus stratified by age groups
<2 years n (%) 2–5 years n (%) 6–15 years n (%) >15 years n (%) P-value
Antibiotics S I R S I R S I R S I R
Oxacillin 27 (100) 0 0 42(100) 0 0 33 0 0 38 0 0
Chloramphenicol 23 (85.2) 4 (14.8) 0 39 (92.9) 3 (7.1) 0 31(93.9) 2 (6.1) 0 38 (100) 0 0 0.121
Erythromycin 12 (44.4) 15(55.6) 0 23 (54.8) 19(45.2) 0 25(78.8) 8 (24.2) 0 29 (76.3) 9(23.7) 0 0.015
Sulphamethoxazole
trimethoprim
15 (55.6) 3 (11.1) 9 (33.3) 36 (85.7) 2 (4.8) 4 (9.5) 26(78.8) 3 (9.1) 4 (12.1) 31 (81.6) 3 (7.9) 4 (10.5) 0.1
Tetracycline 13 (48.2) 1 (3.7) 13(48.2) 31 (73.8) 1 (2.4) 10(23.8) 20(60.6) 1 (3) 12(36.4) 24 (63.2) 1 (2.6) 13(34.2) 0.547
Cefotaxime 26 (96.3) 1 (3.7) 0 38 (90.5) 4 (9.5) 0 31(93.9) 2 (6.1) 0 36 (94.7) 2 (5.3) 0 0.778
S sensitive, I intermediate resistance, R resistant
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Table 2 Distribution of sequence types of S. aureus and S. pneumoniae carriage obtained from this study
S. aureus ST S. aureus Allelic profiles S. pneumoniae carriage
arcC aroE glp gmk pta tpi yqiL Yes No
1 1 1 1 1 1 1 1 1
5 1 4 1 4 12 1 10 2 2
6 12 4 1 4 12 1 3 2
8 3 3 1 1 4 4 3 1
15 13 13 1 1 12 11 13 22 6
25 4 1 4 1 5 5 4 1
30 2 2 2 2 6 3 2 1
41 2 2 2 3 6 3 2 1
45 10 14 8 6 10 3 2 1
72 1 4 1 8 4 4 3 1 1
97 3 1 1 1 1 5 3 1
121 6 5 6 2 7 14 5 1
152 46 75 49 44 13 68 60 1 2
199 13 13 1 1 12 1 13 1
508 10 40 8 6 10 3 2 2 1
509 1 26 28 18 18 33 27 3
567 10 1 1 1 1 1 1 2
669 3 1 94 1 29 5 3 1
707 18 71 6 2 7 58 2 1 1
728 1 3 1 14 11 27 10 1
730 1 4 1 4 97 1 10 2
1004 8 163 129 19 6 125 117 1 1
1320 2 2 2 2 6 11 2 1
1472 2 2 2 2 6 3 162 1
1972 13 13 149 1 12 11 13 1
1973 1 26 28 18 18 11 27 1
1974 10 4 1 1 1 1 1 1
1975 3 1 1 1 1 11 3 1
1976 13 13 1 1 12 11 27 1
1977 10 13 1 1 10 11 13 1
1978 10 40 1 6 220 33 2 1
1979 1 40 8 6 220 3 10 1
1980 13 13 14 1 13 11 13 1
1981 13 13 28 1 12 11 13 1
1982 1 4 1 1 12 5 3 1
1983 10 40 8 1 10 3 2 1
1984 13 13 1 1 12 3 2 1
1985 1 26 28 1 18 33 27 1
1986 3 13 1 1 18 11 3 1
1987 4 2 2 2 12 11 4 1
1988 10 47 8 26 26 3 2 1
1989 3 1 14 1 29 5 3 1
1990 13 1 1 1 12 11 3 1
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dataset into 11 clonal complexes and 21 singletons.
ST15, ST5 and ST188 were the largest predicted found-
ing genotype in an eBURST analysis comparing our
dataset to STs in the MLST database (Fig. 1). Analysis
using a hierarchic unweighted pair group method
(UPMGA) with averaging to generate a dendrogram
showed no clustering in age group, antibiotic resistance,
sex, ethnic group or any other measured parameter.
Minimum spanning tree showed a widespread distribu-
tion of Gambian clones worldwide (Fig. 2).
Association between S. aureus and S. pneumoniae
Eighty two percent of study individuals were S. pneumo-
niae carriers (494/600) and S. pneumoniae carriage
Table 2 Distribution of sequence types of S. aureus and S. pneumoniae carriage obtained from this study (Continued)
1991 3 3 1 1 4 5 3 1
1992 22 1 8 18 12 4 31 1
1993 1 13 1 4 12 1 10 1
1994 1 1 1 4 12 11 10 1
1995 1 1 4 1 5 5 4 1
1996 1 3 1 1 11 27 10 1
1997 13 13 1 1 1 33 13 1
1998 1 4 1 4 10 1 10 1
1999 3 1 94 1 1 5 3 1
2000 4 4 1 4 12 11 3 1
2001 10 13 1 1 1 11 13 1
2002 1 1 1 4 5 1 10 1
2003 1 4 1 4 97 1 100 1
2004 13 13 1 1 12 11 35 1
2005 1 1 28 18 18 33 162 1
2006 1 26 28 18 18 33 13 1
Total 100
New alleles and sequence types are Bolded
Fig. 1 An eBURST derived population snapshot of S. aureus highlighting our dataset. Circles represent the STs. The blue circle represents the
primary founder; yellow represents the subgroup founders; black represents all other STs. Pink fonts represent STs found both in our dataset and
entire MLST database, while fonts in green are STs unique to our dataset
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prevalence decreased with increasing age group [94.7 %
(142/150) for children < 2 years; 93.3 % (140/150) for
children 2 to < 5 years; 84.7 % (127/150) for ages 5 to <
15 years and 56.7 % (85/150) for individuals ≥ 15 years;
p < 0.0001]. Overall, S. aureus carriage among pneumo-
coccal carriers was slightly lower than among non-
pneumococcal carriers (24.3 versus 29.3 %; p = 0.324).
Similarly, when stratified by the 4 different age groups,
there was no association of carriage between these two
bacteria and age group (Table 3). However, there was
a non-significant trend in the younger age groups
(children < 2 years and children 2 to < 5 years of age)
of being S. aureus carriers if they were not S. pneu-
moniae carriers. Analysis of pooled data for these 2
Fig. 2 Clustering of STs using minimum spanning tree. Each circle represents an ST. The area of each circle corresponds to the number of
isolates. The length of the lines represents the number of locus variants. Thick, short, solid lines connect single locus variants and thin longer solid
lines connect double-locus variants. Red portions represent Gambian STs and green portions represent STs found in the rest of the world
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age groups showed a statistically significant inverse
association (24.1 and 50.0 % for S. aureus carriage among
S. pneumoniae carriers and non-carriers respectively;
p = 0.015). Table 4.
Discussion
In this study, we documented a description of nasopha-
ryngeal carriage of S. aureus including the rates of naso-
pharyngeal carriage of S. aureus across age groups,
antibiotic resistance patterns and circulating sequence
types among healthy Gambians prior to the introduction
of routine pneumococcal vaccination as part of the
Extended Programme of Immunization in the country.
This study adds to the very few published studies on
nasopharyngeal carriage of S. aureus in Africa.
An overall S. aureus carriage of 25.2 % reported in this
study is comparable to rates reported previously in other
regions in the world with a range of 10–55 % prevalence
[10, 23, 24]. Similar carriage rates have also been
reported in Africa [25–28], including a setting with
HIV- infected population [27].
Our study has revealed a diversity of clones of S. aureus
circulating in this Gambian population. The discovery of
59 sequence types and 11 clonal complexes show that
there is significant “clonal dissemination” within this
population structure, deriving mostly from CC15 and
CC5. Gambian STs clustered with STs from other parts of
the world, suggesting the dissemination of S. aureus could
be global. It could also suggest that S. aureus lineages are
highly adaptable to various environments and can spread
widely. It is also plausible that proximity of S. aureus
carriage strains to each other within the nasopharynx
could facilitate high mutation or recombination rates,
resulting in carriage of a diverse range of clones.
Although our study has focused on S. aureus carriage
in healthy individuals, a high number of clones identified
in our study population have been identified previously
as a cause of bacterial disease in other parts of the
world. This has been the case for ST1, ST30 and ST121,
which have been described as worldwide pandemic
clones [29, 30]. In Nigeria, STs belonging to CC5, CC15,
CC30, CC97 were associated with otitis media, urinary
tract infection, semen (infertility) and wound infection
[31]. Also, the Spa protein an important virulence factor
for S. aureus [32] was associated with ST15, ST30 and
ST72 carried in the nasopharynx of African Babongo
Pygmies [33]. It is arguable that these latter clones could
be harbouring a latent virulence in our settings. Further
studies are needed to evaluate virulence factors as well
as invasiveness of S. aureus clones in our population.
Our findings indicate that resistance of S. aureus to
Sulphamethoxazole-trimethoprim, the current first line
treatment for non-severe pneumonia in most developing
countries, including The Gambia (WHO IMCI ARI
treatment guidelines; Gambia Government Antibiotic
guidelines for treatment of ARI) could be as high as
15 %. This finding as well as any similar findings from
other research could provide valuable evidence for re-
view of existing national ARI antibiotic treatment pol-
icies. Given the growing scourge of MRSA globally and
its’ attendant risks to both health workers and the gen-
eral public [6], it is significant that there were no MRSA
identified in our study population. It is also noteworthy
that data from the MLST database indicates that methi-
cillin resistance reported for other regions of the world
for ST15, the predominant ST in our study population,
was much lower compared to methicillin resistance to
other STs (http://saureus.mlst.net). This observation further
supports our finding of no MRSA amongst S. aureus iso-
lates in our study population. Additionally, a recent review
on the molecular epidemiology of methicillin resistant S.
aureus in Africa has shown that there was no methicillin
resistance reported for ST15 from the 34 studies conducted
in 15 countries and that CC5 was the predominant clonal
complex [34].
In a population of high prevalence of S. pneumoniae
carriage, our data are indicative of an inverse relation-
ship between nasopharyngeal carriage of S. aureus and
carriage of S. pneumoniae in the younger age groups and
is consistent with finding in a longitudinal study
amongst Gambian newborns followed up to the age of
1 year [12]. This longitudinal study reported that S. aur-
eus carriage was inversely related to S. pneumoniae car-
riage in the first year of life. Our findings are also
consistent with findings from previous studies in
Table 3 Association between S. aureus and S. pneumoniae by
age groups
Age groups S. aureus S. pneumoniae p - value
No N (%) Yes N (%)
Under 2 years No 5 (62.5) 115(81) 0.198
Yes 3 (37.5) 27(19)
2-under 5 years No 4 (40) 99 (70.7) 0.072
Yes 6 (60) 41 (29.3)
5-under 15 years No 19 (82.6) 96 (75.6) 0.597
Yes 5 (17.4) 31 (24.4)
15 and above years No 47 (72.3) 64 (75.2) 0.710
Yes 18 (27.7) 21 (24.7)
Table 4 Association between S. aureus and S. pneumoniae in
two age strata
S. aureus S. pneumoniae p - value
No N (%) Yes N (%)
Under 5 years No 9(50) 214(75.9) 0.015
Yes 9(50) 68(24.1)
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different parts of the world carried out before and after
pneumococcal vaccine introduction [10, 12, 13, 35].
However, other studies have found no such inverse rela-
tionship between these two organisms in nasopharyngeal
carriage [36]. Nevertheless, most studies conducted so far
indicate that pneumococcal vaccination has not had a sus-
tained impact on S. aureus carriage. A possible explanation
may be that currently used pneumococcal vaccines have
been linked with an increase in pneumococcal non-vaccine
serotypes thereby maintaining a large pool of circulating
pneumococcal serotypes. However, as efforts continue
towards the use of protein based pneumococcal vaccines,
the possibility of species replacement may arise and S.
aureus may be a potential replacement pathogen.
We are mindful of a few caveats to be considered in
the interpretation of findings from our study. Given that
our study was conducted in a rural area with very lim-
ited access to antibiotics, generalization of the findings
to other settings should be with some caution. Antibiotic
susceptibility patterns could be different in other regions
of Africa with better access to antibiotics and/or a more
prevalent practice of self-medication. Our finding of
total absence of methicillin resistance to S. aureus may
not be representative of such high antibiotic use settings.
We note also the inverse relationships we have reported
between S. pneumoniae and S. aureus nasopharyngeal
carriage in younger age groups could be confounded by
certain risk factors of carriage, which we have not
evaluated.
Studies after pneumococcal vaccine introduction in
The Gambia will evaluate the effect of vaccine on rate of
S. aureus carriage and this pre-vaccination study will be
of high importance.
Conclusions
We report that nasopharyngeal carriage of S. aureus in
rural Gambia is high in all age groups, with approximately
1 out of 4 individuals being carriers in the pre-
pneumococcal vaccination era. There are indications that
nasopharyngeal carriage of S. aureus could be inversely
related to carriage of S. pneumoniae amongst younger
children in The Gambian and that S. aureus clones in The
Gambia show significant genetic diversity suggesting
worldwide dissemination. These findings could provide a
useful background for impact studies evaluating the intro-
duction of pneumococcal vaccines or other interventions
targeted at the control of S. aureus infection and disease.
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